Combination therapy of methylphenidate and Risperidone on ADHD children

Combination effect of methylphenidate and Risperidone in treatment of children with Attention-Deficit/Hyperactivity Disorder.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200114046125N1

Enrollment

Registered

2020-05-17

Start date

2017-11-22

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD. Attention-deficit hyperactivity disorder, combined type

Interventions

Intervention 1: Intervention group: Ritalin(Methylphenidate) and Risperidone.Methylphenidate is started at a dose of 2.5 mg twice daily and gradually (every week) increased based on the therapeutic re

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: having ADHD criteria age of 6 -12 years

Exclusion criteria

Exclusion criteria: presence of any physical disorder mental retardation psychiatric comorbid disorders such as tic or other developmental disorders history of bipolar disorder, Tourette syndrome, epilepsy, brain damage, or any other neurologic or genetic disorder

Design outcomes

Primary

Measure	Time frame
Treatment of ADHD. Timepoint: at baseline, 2-, 3-, 4- and 6-week after starting the drugs administration. Method of measurement: ADHD Rating Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Assarian

Kashan University of Medical Sciences

f_assar@gmail.com+98 31 5554 9111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026